Clinical Trials
11 trialsNCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT06299163 2025-07-23
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
Phase 1 Terminated
NCT04682431 2024-03-22
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT04691375 2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
Phase 1 Terminated
NCT05498597 2023-10-19
AMT-151 in Patients With Selected Advanced Solid Tumours
Multitude Therapeutics Inc.
Phase 1 Unknown
NCT02900664 2022-03-29
A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)
Novartis
Phase 1 Completed
NCT00101972 2022-02-22
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
MacroGenics
Phase 1 Completed
NCT00003002 2019-02-27
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
University of Washington
Phase 1 Completed
NCT02485119 2018-06-04
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
Bayer
Phase 1 Completed
NCT00005023 2017-11-30
Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer
University of Washington
Phase 1 Completed